Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Prunus domestica extract is derived from the bark of the Prunus domestica tree. Its active constituents include phytosterols (such as beta-sitosterol), pentacyclic triterpenoids (like ursolic and oleaic acids), and ferulic esters of long-chain fatty alcohols. The phytosterols, particularly beta-sitosterol, are known for their anti-inflammatory properties, primarily by inhibiting the synthesis of prostaglandins. This action helps to reduce elevated prostaglandin levels, making it potentially useful in conditions such as Benign Prostatic Hyperplasia (BPH). It is administered as a dietary supplement.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Prunus domestica extract.